natgillin/translations-raw huggingface dataset:
Co-administration of delamanid with a strong inhibitor of CYP3A (as lopinavir/ritonavir) may increase exposure to delamanid metabolite, which has been associated with QTc prolongation.
Istodobna primjena delamanida sa snažnim inhibitorom CYP3A (poput lopinavira/ritonavira) može povisiti izloženost metabolitu delamanida, koji je povezan s produljenjem QTc intervala.
Mild renal tubular degeneration was confined to mice exposed with at least twice the recommended human exposure; the kidney was unaffected in rats and dogs.
Blaga degeneracija bubrežnih kanalića uočena je u miševa u kojih je izloženost bila najmanje dvostruko veća od one preporučene u ljudi; ni u štakora ni u pasa nije bilo učinaka na bubrege.
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g. beclomethasone).
Mora se razmotriti smanjenje doze glukokortikoida i pažljivo pratiti lokalne i sistemske učinke, ili prijeći na primjenu glukokortikoida koji nije supstrat enzima CYP3A4 (npr.
Ranitidine: ↔
Ranitidin: ↔
Phosphodiesterase(PDE5) inhibitors Avanafil (ritonavir 600 mg BID)
Inhibitori fosfodiesteraze 5 (PDE5) Avanafil (ritonavir 600 mg BID)
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Kod bolesnika zaraženih HIV-om s teškom imunodeficijencijom u trenutku započinjanja kombinirane antiretrovirusne terapije (CART) može se pojaviti upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
It may be difficult to tell which side effects have been caused by Kaletra and which may occur due to other medicines you take at the same time or by the complications of the HIV infection.
Katkada je teško razlikovati nuspojave koje uzrokuje Kaletra od onih koje mogu biti uzrokovane drugim lijekovima koje uzimate istovremeno s lijekom Kaletra, odnosno od komplikacija same infekcije HIVom.
The safety of Kaletra has been investigated in over 2600 patients in Phase II-IV clinical trials, of which over 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily.
Sigurnost lijeka Kaletra je ispitana u kliničkim ispitivanjima faze II-IV na preko 2600 bolesnika, od kojih je preko 700 primilo dozu od 800/200 mg (6 kapsula ili 4 tablete) jednom dnevno.
Protocol defined non-inferiority of once-daily dosing compared with twice-daily dosing was demonstrated if the lower bound of the 95% confidence interval for the difference in proportion of subjects responding (once daily minus twice daily) excluded -12% at Week 48.
Protokolom definirana neinferiornost doziranja jednom dnevno naspram doziranja dva puta dnevno dokazana je ako donja granica 95%-tnog intervala pouzdanosti za razliku u udjelu ispitanika s odgovorom (jednom dnevno minus dva puta dnevno) ne prelazi -12 % u 48. tjednu.
• antibiotics (e.g. rifabutin, rifampicin, clarithromycin);
• antibiotici (npr. rifabutin, rifampicin, klaritromicin);
The following events have been reported in association with unintended overdoses in preterm neonates: complete atrioventricular block, cardiomyopathy, lactic acidosis, and acute renal failure.
Prijavljeni su sljedeći događaji povezani s nenamjernim predoziranjem kod prijevremeno rođene djece: potpuni atrioventrikularni blok, kardiomiopatija, laktička acidoza i akutno zatajenje bubrega.
Kaletra oral solution is contraindicated in children below the age of 14 days, pregnant women, patients with hepatic or renal failure and patients treated with disulfiram or metronidazole due to the potential risk of toxicity from the excipient propylene glycol (see section 4.4).
Kaletra oralna otopina kontraindicirana je u djece mlađe od 14 dana, trudnica, bolesnika sa zatajenjem jetre ili bubrega i bolesnika liječenih disulfiramom ili metronidazolom, zbog mogućeg rizika od toksičnosti pomoćne tvari propilenglikola (vidjeti dio 4.4).
Herbal preparations containing St John's wort must not be combined with lopinavir and ritonavir.
Biljni pripravci koji sadrže gospinu travu ne smiju se kombinirati s lopinavirom ni ritonavirom.
Ranolazine
Ranolazin
Each 1 ml contains 356.3 mg of alcohol (42.4% v/v), 168.6 mg of high fructose corn syrup, 152.7 mg of propylene glycol (15.3% w/v) (see section 4.3), 10.2 mg of polyoxyl 40 hydrogenated castor oil and 4.1 mg of acesulfame potassium (see section 4.4).
Svakih 1 ml sadrži 356,3 mg alkohola (42,4% V/V), 168,6 mg kukuruznog sirupa bogatog fruktozom, 152,7 mg propilenglikola (15,3% m/V) (vidjeti dio 4.3), 10,2 mg polioksil 40 hidrogeniranog ricinusovog ulja i 4,1 mg acesulfamkalija (vidjeti dio 4.4).
• protease inhibitors (e.g. fosamprenavir, indinavir, ritonavir, saquinavir, tipranavir);
• inhibitori proteaze (npr. fosamprenavir, indinavir, ritonavir, sakvinavir, tipranavir);
• ranolazine (used to treat chronic chest pain [angina]);
• ranolazin (lijek za liječenje kronične boli u prsištu [angine]);
Strong CYP3A4 inhibitors such as protease inhibitors may increase bedaquiline exposure which could potentially increase the risk of bedaquiline-related adverse reactions.
Snažni inhibitori CYP3A4 poput inhibitora proteaza mogu povisiti izloženost bedakilinu što može potencijalno dovesti do povećanog rizika od nuspojava uzrokovanih bedakilinom.
Pimozide
Pimozid
Cyclosporin, Sirolimus (rapamycin), Tacrolimus:
Ciklosporin, sirolimus (rapamicin), takrolimus:
Co-administration of rivaroxaban and Kaletra may increase rivaroxaban exposure which may increase the risk of bleeding.
Istodobna primjena rivaroksabana i lijeka Kaletra može povećati izloženost rivaroksabanu što može povećati rizik od krvarenja.
Therefore, combination of bedaquiline with lopinavir/ritonavir should be avoided.
Stoga se mora izbjegavati kombinacija bedakilina i lopinavira/ritonavira.
Virologic failure* *Defined as confirmed plasma HIV-1 RNA level > 400 copies/ml at 24 weeks or viral rebound > 4000 copies/ml after Week 24.
*Definira se kao potvrđena plazmatska razina HIV-1 RNK > 400 kopija/ml u 24. tjednu ili ponovni porast broja virusa na > 4000 kopija/ml nakon 24. tjedna.
HCV protease inhibitors Simeprevir 200 mg daily (ritonavir 100 mg BID)
Inhibitori HCV proteaze Simeprevir 200 mg dnevno (ritonavir 100 mg BID)
• medicines used for smoking cessation (e.g. bupropion);
• lijekovi koji se koriste kod prestanka pušenja (npr. bupropion);
Manufacturer:
Proizvođači:
Microsomal triglyceride transfer protein (MTTP) inhibitor
Inhibitor mikrosomalnog proteina za prijenos triglicerida (engl. microsomal triglyceride transfer protein, MTTP)
Pull up the plunger until the correct dose amount is shown on the plunger.
Izvlačite klip sve dok na njemu ne vidite točnu dozu.
• You must not take Kaletra with sildenafil used to treat pulmonary arterial hypertension (high blood pressure in the pulmonary artery) (see also Do not take Kaletra section above).
• Ne smijete uzimati lijek Kaletra sa sildenafilom koji se koristi za liječenje plućne arterijske hipertenzije (visok krvni tlak u plućnoj arteriji) (pogledajte prethodno naveden dio Nemojte uzimati lijek Kaletra).
In post-marketing surveillance through the Antiretroviral Pregnancy Registry, established since January 1989, an increased risk of birth defects exposures with Kaletra has not been reported among over 1000 women exposed during the first trimester.
U praćenju nakon stavljanja lijeka u promet kroz Registar trudnoća izloženih antiretroviralnim lijekovima „Antiretroviral Pregnancy Registry” utemeljen u siječnju 1989. nije zabilježen povećan rizik od kongenitalnih oštećenja kod više od 1000 žena koje su bile izložene lijeku Kaletra tijekom prvog tromjesečja.
At least 13 lopinavir oxidative metabolites have been identified in man.
U čovjeka je otkriveno najmanje 13 metabolita koji su proizvod oksidacijskog metabolizma lopinavira.
Mechanism of interaction
Mehanizam interakcije
Blood glucose disorders including diabetes mellitus, hypertriglyceridaemia, hypercholesterolemia, weight decreased, decreased appetite
Poremećaj glukoze u krvi, uključujući diabetes mellitus, hipertrigliceridemiju, hiperkolesterolemiju, smanjenje tjelesne težine, smanjenje apetita
Antianginal Ranolazine
Antianginici Ranolazin
• 120 ml (2 bottles x 60 ml).
• 120 ml (2 boce x 60 ml).
For Kaletra oral solution, the corresponding increases in lopinavir AUC and Cmax were 80% and 54%, respectively.
Pri uzimanju Kaletra oralne otopine odgovarajući porast vrijednosti AUC odnosno Cmax lopinavira iznosio je, redom, 80% i 54%.
Therefore, this co-administration should be avoided unless judged strictly necessary.
Stoga se istodobna primjena tih lijekova treba izbjegavati, osim ako se ona ne ocijeni doista nužnom.
• inflammation of blood vessels and capillaries;
• upala krvnih žila i kapilara;
• Nausea, vomiting, abdominal pain, difficulty breathing and severe weakness of the muscles in the legs and arms as these symptoms may indicate raised lactic acid levels.
• Mučninu, povraćanje, bol u trbuhu, otežano disanje i tešku slabost mišića u nogama i rukama jer ti simptomi mogu upućivati na povećanu koncentraciju mliječne kiseline.
Saquinavir 1000 mg BID
Sakvinavir 1000 mg BID
Study P1060 was a randomised controlled trial of nevirapine versus lopinavir/ritonavir-based therapy in subjects 2 to 36 months of age infected with HIV-1 who had (Cohort I) and had not (Cohort II) been exposed to nevirapine during pregnancy for prevention of mother-to-child transmission.
Ispitivanje P1060 bilo je randomizirano, kontrolirano ispitivanje nevirapina u odnosu na terapiju utemeljenu na lopinaviru/ritonaviru, provedeno u ispitanika u dobi od 2 do 36 mjeseci zaraženih virusom HIV-1 koji su tijekom trudnoće bili izloženi liječenju nevirapinom radi sprječavanja prijenosa infekcije s majke na dijete (kohorta I) i onih koji nisu bili izloženi takvom liječenju nevirapinom
Pravastatin is not metabolised by CYP450.
Pravastatin se ne metabolizira putem CYP450.
• The usual adult dose is 5 ml of the oral solution twice a day i.e. every 12 hours, in combination with other anti-HIV medicines.
• Uobičajena doza za odrasle je 5 ml oralne otopine dva puta dnevno, tj. svakih 12 sati u kombinaciji s drugim anti-HIV lijekovima.
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin.
Upozorava se na pojačano praćenje nuspojava povezanih s rifabutinom uključujući neutropeniju i uveitis zbog očekivanog povećanja izloženosti rifabutinu.
Total amounts of alcohol and propylene glycol from all medicines, including Kaletra oral solution, that are to be given to infants should be taken into account in order to avoid toxicity from these excipients (see section 4.4).
Potrebno je uzeti u obzir ukupnu količinu alkohola i propilenglikola iz svih lijekova koji se daju maloj djeci, uključujući Kaletra oralnu otopinu, kako bi se izbjegla toksičnost uzrokovana tim pomoćnim tvarima (vidjeti dio 4.4).
Herbal products St John's wort (Hypericum perforatum)
Biljni pripravci Gospina trava (Hypericum perforatum)
Kaletra 100 mg/25 mg film-coated tablets are supplied in plastic bottles containing 60 tablets.
Kaletra 100 mg/25 mg filmom obložene tablete su dostupne u plastičnim bocama koje sadrže 60 tableta.
The median follow-up was 48 weeks in Cohort I and 72 weeks in Cohort II.
I te 72 tjedna u kohorti II.
Kaletra must not be given to these patients (see section 4.3).
Kaletra se tim bolesnicima ne smije davati (vidjeti dio 4.3).
Kaletra 400/100 mg + ritonavir 300 mg) twice daily has allowed compensating for the CYP 3A4 inducer effect of rifampicin.
Kaletra 400/100 mg + ritonavir 300 mg) dvaput na dan kompenziran je indukcijski učinak rifampicina na CYP 3A4.
If the co-administration of Kaletra with bupropion is judged unavoidable, this should be done under close clinical monitoring for bupropion efficacy, without exceeding the recommended dosage, despite the observed induction.
Ako se istodobna primjena lijeka Kaletra s bupropionom ocijeni neizbježnom, lijekove treba davati uz pomno kliničko praćenje djelotvornosti bupropiona, pazeći da se unatoč opaženoj indukciji ne prekorače preporučene doze.
Lamotrigine:
Lamotrigin:
However, if it is judged necessary to resort to solid oral dosage form for children weighing less than 40 kg or with a BSA between 0.5 and 1.4 m2 and able to swallow tablets, Kaletra 100 mg/25 mg tablets may be used.
Ako se, međutim, ocijeni da je nužno davati čvrste peroralne farmaceutske oblike djetetu koje teži manje od 40 kg ili s PT-om između 0,5 i 1,4 m2 koje može progutati tabletu, mogu se koristiti Kaletra 100 mg/25 mg tablete.
The 4-oxo and 4-hydroxymetabolite epimeric pair are the major metabolites with antiviral activity, but comprise only minute amounts of total plasma radioactivity.
Epimerni par 4-okso- i 4hidroksimetabolita glavni su metaboliti s antivirusnim djelovanjem, no njihov je udio u ukupno izmjerenoj radioaktivnosti u plazmi neznatan.
• Always keep enough Kaletra on hand so you don't run out.
• Pazite da uvijek imate dovoljno lijeka Kaletra kako Vam ne bi ponestalo lijeka.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you or your child.
Vi ili Vaše dijete počnete uzimati ovaj lijek jer sadrži Vama važne podatke.
For children 2 weeks or older and weighing up to 15 kg
Za djecu u dobi od 2 tjedna ili stariju i tjelesne težine do 15 kg.
• rash, eczema, accumulation of scales of greasy skin;
• osip, ekcem, nakupljanje ljuskica masne kože;
Therefore, the antiviral activity of Kaletra is due to lopinavir.
Za antivirusnu aktivnost lijeka Kaletra odgovoran je lopinavir.
The risk of diarrhoea may be greater with once-daily dosing of Kaletra.
Rizik od proljeva se može povećati s doziranjem lijeka Kaletra jednom dnevno.
The 2 bottle pack also contains two 2 ml syringes with 0.1 ml graduations.
Pakiranje s 2 boce sadrži i 2 štrcaljke od 2 ml s oznakama od 0,1 ml.
Lopinavir/ritonavir 800/200 mg QD was administered with ombitasvir/paritaprevir/ritonavir with or without dasabuvir.
Lopinavir/ritonavir 800/200 mg QD primjenjivao se s ombitasvirom/ paritaprevirom/ritonavirom u kombinaciji s dasabuvirom ili bez njega.
At 30 weeks age of gestation, the dose was increased to 500/125 mg (two 200/50 mg tablets plus one 100/25 mg tablet) twice daily until subjects were 2 weeks postpartum.
U gestacijskoj dobi od 30 tjedana doza je povećana na 500/125 mg (dvije 200/50 mg tablete i jedna 100/25 mg tableta) dvaput na dan do razdoblja od 2 tjedna nakon poroda.
Caution must also be exercised and reduced doses should be considered if Kaletra is used concurrently with rosuvastatin.
Oprez je također nužan te se mora razmotriti smanjenje doze ako se Kaletra daje istodobno s rosuvastatinom.
Children were eligible when they were aged <18 years, ≥15 kg in weight, receiving cART that included lopinavir/ritonavir, HIV-1 ribonucleic acid (RNA) <50 copies/ml for at least 24 weeks and able to swallow tablets.
Djeca su morala imati <18 godina, ≥15 kg tjelesne težine, primati cART koji uključuje lopinavir/ritonavir, imati HIV-1 ribonukleinsku kiselinu (RNK) <50 kopija/ml najmanje 24 tjedna te su morala moći progutati tablete.
Thyroid hormone replacement therapy Levothyroxine
Nadomjesna terapija tireoidnog hormona Levotiroksin
The percentage of patients with confirmed viral rebound >50 copies/ml during 48 weeks of follow-up was higher in the paediatric patients receiving lopinavir/ritonavir tablets once daily (12%) than in patients receiving the twice-daily dosing (8%, p = 0.19), mainly due to lower adherence in the once-daily group.
Postotak bolesnika s potvrđenim ponovnim porastom broja virusa (rebound) >50 kopija/ml tijekom 48 tjedana praćenja je bio viši u pedijatrijskih bolesnika koji su primali lopinavir/ritonavir tablete jednom dnevno (12%) u odnosu na bolesnike koji su primali lopinavir/ritonavir dvaput na dan (8%, p=0,19), uglavnom zbog slabije adherencije bolesnika u skupini koja je primala lijek jednom dnevno.
AUC: ↑ 5.9-fold
AUC: ↑ 5,9 puta
• lovastatin, simvastatin (used to lower blood cholesterol);
• lovastatin, simvastatin (lijek za snižavanje kolesterola u krvi);
Table 8
Tablica 8
Patients had a mean age of 5 years (range 6 months to 12 years) with 14 patients less than 2 years old and 6 patients one year or less.
(raspon: od 6 mjeseci do 12 godina), pri čemu je 14 bolesnika bilo mlađe od 2 godine, a njih 6 bilo je u dobi od jedne godine ili mlađe.
Co-administration of voriconazole and low dose ritonavir (100 mg BID) as contained in Kaletra should be avoided unless an assessment of the benefit/risk to patient justifies the use of voriconazole.
Mora se izbjegavati istodobna primjena vorikonazola i ritonavira u niskoj dozi (100 mg BID) kakvu sadrži Kaletra, osim ako ocjena omjera koristi/rizika za bolesnika ne opravdava primjenu vorikonazola.
The signs of toxicity observed in mice, rats or dogs included decreased activity, ataxia, emaciation, dehydration and tremors.
Znakovi otrovanja kod miševa, štakora ili pasa obuhvaćaju smanjenu aktivnost, ataksiju, mršavljenje, dehidraciju i tremor.
The effect on DAAs and lopinavir was similar to that observed when lopinavir/ritonavir 400/100 mg BID was administered (see section 4.3).
Učinak na direktno djelujuće antivirotike i lopinavir bio je sličan onom opaženom kod primjene lopinavira/ritonavira 400/100 mg BID (vidjeti dio 4.3).
For monitoring of blood lipids and glucose, reference is made to established HIV treatment guidelines.
Za nadzor lipida i glukoze u krvi dane su preporuke u utvrđenim smjernicama za liječenje HIV-a.
These changes were reversible with withdrawal of the active substance and were absent in mice and dogs.
Te su promjene bile reverzibilne i stanje se normaliziralo nakon obustave davanja djelatne tvari, a u miševa i pasa te se promjene nisu javile.
The safety and efficacy of Kaletra has not been established in patients with significant underlying liver disorders.
Sigurnost i djelotvornost lijeka Kaletra u bolesnika sa znatnim podležećim poremećajima funkcije jetre nisu ustanovljene.
2 tablets (200/50 mg)
2 tablete (200/50 mg)
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (≥1/10), common (≥ 1/100
Unutar svake grupe učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Bolesnici s kroničnim hepatitisom B ili C, koji primaju kombiniranu terapiju antiretrovirusnim lijekovima, izloženi su povećanom riziku od teških i za život opasnih jetrenih nuspojava.
• For children, your doctor will decide the right dose (number of tablets) based on the child's height and weight.
• Liječnik će odlučiti o odgovarajućoj dozi (broju tableta) lijeka Kaletra za dijete, na temelju djetetove težine i visine.
Lopinavir is essentially completely metabolised by CYP3A.
Lopinavir se gotovo posve metabolizira putem CYP3A.
• colchicine (used to treat gout) if you have kidney and/or liver problems (see the section on
• kolhicin (lijek za liječenje gihta) ako imate tegobe s bubrezima i/ili jetrom (pogledajte dio
Overall, the in vitro characterisation of phenotypic cross-resistance between lopinavir and other protease inhibitors suggest that decreased susceptibility to lopinavir correlated closely with decreased susceptibility to ritonavir and indinavir, but did not correlate closely with decreased susceptibility to amprenavir, saquinavir, and nelfinavir.
Sveukupno, in vitro karakterizacija fenotipske križne rezistencije između lopinavira i ostalih inhibitora proteaze upućuje na zaključak da smanjena osjetljivost na lopinavir pokazuje jasnu korelaciju sa smanjenom osjetljivošću na ritonavir i indinavir, a da nema jasne korelacije sa smanjenom osjetljivošću na amprenavir,
Ritonavir inhibits the metabolism of lopinavir, thereby increasing the plasma levels of lopinavir.
Ritonavir inhibira metabolizam lopinavira, čime povećava razinu lopinavira u plazmi.
• ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to treat headaches);
• ergotamin, dihidroergotamin, ergonovin, metilergonovin (lijekovi za liječenje glavobolje);
• deep vein inflammation related to a blood clot;
• duboka venska upala povezana s krvnim ugruškom;
In rats, embryofoetotoxicity (pregnancy loss, decreased foetal viability, decreased foetal body weights, increased frequency of skeletal variations) and postnatal developmental toxicity (decreased survival of pups) was observed at maternally toxic dosages.
U štakora je, pri dozama koje izazivaju materinsku toksičnost, uočena embriofetotoksičnost (pobačaj, smanjena životnost ploda, smanjena tjelesna težina ploda, povećana učestalost promjena skeleta) i toksičnost tijekom postnatalnog razvoja (smanjeno preživljenje mladunčadi).
To date, there is limited human experience of acute overdose with Kaletra.
Zasad su iskustva o akutnom predoziranju lijekom Kaletra u čovjeka ograničena.
This list is not intended to be inclusive or comprehensive.
Ovaj popis interakcija nije sveobuhvatan i ne uključuje sve moguće interakcije.
Adverse reactions from clinical trials and post-marketing experience in adult and paediatric patients:
Nuspojave iz kliničkih ispitivanja i praćenja nakon stavljanja lijeka na tržište kod odraslih i pedijatrijskih bolesnika:
Kaletra does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).
Kaletra pri klinički značajnim koncentracijama ne inhibira CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 ni CYP1A2 (vidjeti dio 4.3).
The enrolled population was moderately PI-experienced with more than half of patients having never received prior PI and around 80% of patients presenting a viral strain with less than 3 PI mutations.
Uključena populacija bila je umjereno izložena inhibitorima proteaze (IP) s više od pola bolesnika koji nikad prije nisu primali IP i oko 80% bolesnika u kojih je bio prisutan virusni soj s manje od 3 mutacije IP.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment should be considered.
Jave li se u tih bolesnika znaci pogoršanja bolesti jetre, mora se razmotriti prekid ili ukidanje terapije.
• vertigo (spinning feeling);
• vrtoglavica (osjećaj vrtnje);
• In use storage: If kept outside of the refrigerator, do not store above 25°C and discard any unused contents after 42 days (6 weeks).
• Čuvanje lijeka u primjeni: Ako je izvan hladnjaka, ne čuvati na temperaturi iznad 25 °C, a lijek koji se ne potroši za 42 dana (6 tjedana) mora se zbrinuti.
A limited increase in total lopinavir concentrations of approximately 30% has been observed which is not expected to be of clinical relevance (see section 4.2).
Uočen je ograničeni porast ukupnih koncentracija lopinavira od oko 30 %, no ne očekuje se da bi to moglo biti od kliničkog značaja (vidjeti dio 4.2).
(inhibition of CYP3A enzymes)
(inhibicija CYP3A enzima)
• People taking Kaletra may still develop infections or other illnesses associated with HIV disease and AIDS.
• Ljudi koji uzimaju lijek Kaletra mogu ipak razviti infekcije ili druge bolesti povezane s HIV
nevirapine
nevirapin
The standard recommended dosage of Kaletra tablets is 400/100 mg (two 200/50 mg) tablets twice daily taken with or without food.
Uobičajena preporučena doza Kaletra tableta je 400/100 mg (dvije tablete od 200/50 mg) koja se daje dva puta dnevno s ili bez hrane.
An increase of the dose of Kaletra to 300/75 mg/m2 is needed in these patients.
U tih je bolesnika potrebno povećati dozu lijeka Kaletra na 300/75 mg/m2.
Most tyrosine kinase inhibitors such as dasatinib and nilotinib, vincristine, vinblastine
Većina inhibitora tirozin kinaze kao što su dasatinib i nilotinib, vinkristin, vinblastin
• lower respiratory tract infection;
• infekcije donjih dišnih puteva;